Apyx Medical Corporation (NASDAQ:APYX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Apyx Medical Corporation (NASDAQ:APYX) has received a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $6.60.

APYX has been the subject of several analyst reports. HC Wainwright started coverage on Apyx Medical in a report on Monday, July 13th. They set a “buy” rating and a $7.00 price target for the company. Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research report on Wednesday, June 24th.

Institutional Investors Weigh In On Apyx Medical

A number of institutional investors have recently made changes to their positions in APYX. Nwam LLC bought a new stake in shares of Apyx Medical during the first quarter valued at approximately $47,000. Citadel Advisors LLC bought a new position in Apyx Medical in the 3rd quarter valued at approximately $28,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Apyx Medical during the 2nd quarter valued at $62,000. AXQ Capital LP purchased a new stake in Apyx Medical during the 2nd quarter valued at $78,000. Finally, Hudson Bay Capital Management LP bought a new stake in shares of Apyx Medical in the 4th quarter worth $73,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Apyx Medical Stock Performance

Apyx Medical stock opened at $3.05 on Wednesday. Apyx Medical has a twelve month low of $1.70 and a twelve month high of $5.08. The company has a quick ratio of 4.53, a current ratio of 5.68 and a debt-to-equity ratio of 3.19. The company has a market capitalization of $128.47 million, a P/E ratio of -15.25 and a beta of 1.32. The stock’s 50 day moving average is $3.83 and its 200 day moving average is $3.83.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%.The business had revenue of $13.88 million during the quarter, compared to analysts’ expectations of $13.18 million. On average, equities research analysts predict that Apyx Medical will post -0.25 earnings per share for the current fiscal year.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.